Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study

Detalhes bibliográficos
Autor(a) principal: Silva, Giovanni Faria
Data de Publicação: 2014
Outros Autores: Villela-nogueira, Cristiane A., Mello, Carlos Eduardo Brandao, Soares, Elza Cotrim, Coelho, Henrique Sergio M., Ferreira, Paulo Roberto Abrão [UNIFESP], Ruiz, Fernando Jose Goes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1016/j.bjid.2013.05.007
http://repositorio.unifesp.br/handle/11600/8202
Resumo: Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.
id UFSP_9b829fd942e7d41f3a9237e7a6a2a29b
oai_identifier_str oai:repositorio.unifesp.br/:11600/8202
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life studyHepatitis CAdvanced fibrosisPeginterferonRibavirinBackground: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.Universidade Estadual Paulista (UNESP) Botucatu School of MedicineUniversidade Federal do Rio de JaneiroUniversidade Estadual de CampinasUniversidade Federal de São Paulo (UNIFESP)Pontificia Universidade Catolica de São PauloUNIFESP, EPM, São PauloSciELOBrazilian Society of Infectious DiseasesUniversidade Estadual Paulista (UNESP)Universidade Federal do Rio de JaneiroUniversidade Estadual de Campinas (UNICAMP)Universidade Federal de São Paulo (UNIFESP)Pontificia Universidade Catolica de São PauloSilva, Giovanni FariaVillela-nogueira, Cristiane A.Mello, Carlos Eduardo BrandaoSoares, Elza CotrimCoelho, Henrique Sergio M.Ferreira, Paulo Roberto Abrão [UNIFESP]Ruiz, Fernando Jose Goes2015-06-14T13:46:54Z2015-06-14T13:46:54Z2014-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion48-52application/pdfhttp://dx.doi.org/10.1016/j.bjid.2013.05.007Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014.10.1016/j.bjid.2013.05.007S1413-86702014000100048.pdf1413-8670S1413-86702014000100048http://repositorio.unifesp.br/handle/11600/8202WOS:000332911100008engBrazilian Journal of Infectious Diseasesinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-28T13:18:17Zoai:repositorio.unifesp.br/:11600/8202Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-28T13:18:17Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
title Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
spellingShingle Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
Silva, Giovanni Faria
Hepatitis C
Advanced fibrosis
Peginterferon
Ribavirin
title_short Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
title_full Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
title_fullStr Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
title_full_unstemmed Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
title_sort Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
author Silva, Giovanni Faria
author_facet Silva, Giovanni Faria
Villela-nogueira, Cristiane A.
Mello, Carlos Eduardo Brandao
Soares, Elza Cotrim
Coelho, Henrique Sergio M.
Ferreira, Paulo Roberto Abrão [UNIFESP]
Ruiz, Fernando Jose Goes
author_role author
author2 Villela-nogueira, Cristiane A.
Mello, Carlos Eduardo Brandao
Soares, Elza Cotrim
Coelho, Henrique Sergio M.
Ferreira, Paulo Roberto Abrão [UNIFESP]
Ruiz, Fernando Jose Goes
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (UNESP)
Universidade Federal do Rio de Janeiro
Universidade Estadual de Campinas (UNICAMP)
Universidade Federal de São Paulo (UNIFESP)
Pontificia Universidade Catolica de São Paulo
dc.contributor.author.fl_str_mv Silva, Giovanni Faria
Villela-nogueira, Cristiane A.
Mello, Carlos Eduardo Brandao
Soares, Elza Cotrim
Coelho, Henrique Sergio M.
Ferreira, Paulo Roberto Abrão [UNIFESP]
Ruiz, Fernando Jose Goes
dc.subject.por.fl_str_mv Hepatitis C
Advanced fibrosis
Peginterferon
Ribavirin
topic Hepatitis C
Advanced fibrosis
Peginterferon
Ribavirin
description Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.
publishDate 2014
dc.date.none.fl_str_mv 2014-01-01
2015-06-14T13:46:54Z
2015-06-14T13:46:54Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1016/j.bjid.2013.05.007
Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014.
10.1016/j.bjid.2013.05.007
S1413-86702014000100048.pdf
1413-8670
S1413-86702014000100048
http://repositorio.unifesp.br/handle/11600/8202
WOS:000332911100008
url http://dx.doi.org/10.1016/j.bjid.2013.05.007
http://repositorio.unifesp.br/handle/11600/8202
identifier_str_mv Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014.
10.1016/j.bjid.2013.05.007
S1413-86702014000100048.pdf
1413-8670
S1413-86702014000100048
WOS:000332911100008
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Brazilian Journal of Infectious Diseases
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 48-52
application/pdf
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268311601414144